Pricing Log in Create free account
Friday 6 November 2026 Export ALKS’s income statement to Excel — free account

Alkermes plc

ALKS Healthcare Drug Manufacturers Specialty & Generic

Alkermes plc’s revenue for fiscal 2025 (year ended December 2025) was $1.5 billion, down 5.25% from fiscal 2024.

Revenue
+21.8%
EPS
−80.6%
Free cash flow
+6.78%

Quarter to September 2026, against a year earlier

45.66 1.12 +2.51%
Market cap
$7.5B
P/E
0.0×
Fwd P/E
−85.9×
Dividend yield
—
F-score
7/9
Altman Z
5.33
Beneish M
−3.29
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Alkermes plc 10-Q filed Jul 28, 2026

Fiscal Q2 2026 · Period ended Jun 30, 2026 · Filed · accepted 9:22 AM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors
Previous quarter Same quarter last year

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed May 5, 2026: 7 added · 4 removed · 31 modified; 3 with only figures updated

  1. Modified · Executive Summary

    Net income was $0.5 million or $0.00 per ordinary share—basic and diluted, for the three months ended June 30, 2026 and net loss was $66.566.0 million or $0.40 per ordinary share—basic and diluted, for the threesix months ended March 31June 30, 2026, compared to net income of $22.587.1 million and $109.6 million or $0.14 0.53 and $0.67 per ordinary share—basic and $0.13 0.52 and $0.65 per ordinary share—diluted, for the three and six months ended March 31June 30, 2025, respectively.